Shopping Cart
Remove All
Your shopping cart is currently empty
Tamtuvetmab
(Synonyms: AT-005, AT005) Copy Product Info
🥰Excellent
Synonyms: AT-005, AT005
Catalog No. T81046 Copy Product Info
🥰Excellent
Tamtuvetmab (AT-005) is a caninised version of blontuvetmab targeting CD52. Tamtuvetmab (AT-005) enhances progression-free survival and demonstrates in vivo efficacy in naïve T-cell lymphoma (LSA) models in dogs and has received veterinary approval . Tamtuvetmab (AT-005) is utilized in veterinary oncology research focused on CD52-targeted immune cell depletion, T-cell lymphoma progression mechanisms, and antibody-mediated lymphoid cell modulation.
Tamtuvetmab
Cas No. 1608122-71-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $328 | - | In Stock | |
| 5 mg | $993 | - | In Stock | |
| 10 mg | $1,570 | - | In Stock | |
| 25 mg | $2,890 | - | In Stock | |
| 50 mg | $4,650 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.0% (SDS-PAGE); 98.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tamtuvetmab (AT-005) is a caninised version of blontuvetmab targeting CD52. Tamtuvetmab (AT-005) enhances progression-free survival and demonstrates in vivo efficacy in naïve T-cell lymphoma (LSA) models in dogs and has received veterinary approval . Tamtuvetmab (AT-005) is utilized in veterinary oncology research focused on CD52-targeted immune cell depletion, T-cell lymphoma progression mechanisms, and antibody-mediated lymphoid cell modulation. |
| In vivo | Methods:Diseased dogs were intravenously infused with Tamtuvetmab at a concentration of 5 mg/mL with doses ranging from 7.5 to 30 mL for 15 to 30 minutes. The in vivo efficacy against juvenile T-cell lymphoma (LSA) and adverse reactions were evaluated. Results:This treatment regimen exerted therapeutic effects on diseased dogs, but also caused adverse reactions including vomiting, diarrhea, lethargy, decreased appetite and weight loss [1]. |
| Synonyms | AT-005, AT005 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | CD25 |
| Cas No. | 1608122-71-9 |
| Isotype | Canine lgG lambda |
| Storage | Store at low temperature, -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: Tamtuvetmab in vivo
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.